A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli : A pilot study-Reference-Cited by-同舟云学术

A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli : A pilot study

Published:2017-08 Issue:8 Volume:23 Page:556-562
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Malaisri Chitprasong,Phuphuakrat Angsana,Wibulpolprasert Arrug,Santanirand Pitak,Kiertiburanakul Sasisopin

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Reference42 articles.

1. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs;Foxman;Am J Med,2002

2. The etiology of urinary tract infection: traditional and emerging pathogens;Ronald;Dis Mon,2003

3. β-Lactamase-mediated resistance and opportunities for its control;Livermore;J Antimicrob Chemother,1998

4. Increasing incidence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States;Thaden;Infect Control Hosp Epidemiol,2016

5. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory;Paterson;J Clin Microbiol,2001

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of carbapenems and alternative antimicrobials for treating complicated urinary tract infections caused by third-generation cephalosporin-resistant gram-negative bacteria: A systematic review and meta-analysis of randomised controlled trials;Journal of Infection and Chemotherapy;2024-11

2. Novel Antibiotics in Urology;Guide to Antibiotics in Urology;2024

3. A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study;Clinical and Translational Science;2023-10-28

4. Harnwegsinfektionen einschließlich Pyelonephritis;Medizinische Klinik - Intensivmedizin und Notfallmedizin;2023-06-16

5. New antibiotics for the treatment of urinary tract infections;Die Urologie;2023-06-12